Descartes-08 Retreatment Data Shows 6.6-Point MG-ADL Reduction at Month 12
RNAC sits 29% above its 52-week low of $5.6.
Summary
Cartesian Therapeutics released additional retreatment data for Descartes-08 in myasthenia gravis, showing a mean MG-ADL reduction of 6.6 points at month 12 post retreatment. The median interval between initial treatment and retreatment infusion was 16.6 months, indicating durable responses. No new safety signals were reported. The company also provided updated regulatory timelines: topline data from the Phase 3 AURORA trial is expected in 1Q27, with a BLA filing anticipated in mid-2027. This follows the Q2 2026 earnings report in August, which highlighted a cash runway into 2028. The data supports the potential of Descartes-08 as a meaningful treatment option, and the upcoming Phase 3 readout will be a key milestone.
At the time of this announcement, RNAC was trading at $7.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.1M. The 52-week trading range was $5.60 to $11.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.